- Home
- GRWG vs SPRO Comparison
GRWG vs SPRO Comparison
Compare GRWG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRWG
- SPRO
- Stock Information
- Founded
- GRWG 2008
- SPRO 2013
- Country
- GRWG United States
- SPRO United States
- Employees
- GRWG N/A
- SPRO N/A
- Industry
- GRWG RETAIL: Building Materials
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- GRWG Consumer Discretionary
- SPRO Health Care
- Exchange
- GRWG Nasdaq
- SPRO Nasdaq
- Market Cap
- GRWG 98.0M
- SPRO 107.5M
- IPO Year
- GRWG N/A
- SPRO 2017
- Fundamental
- Price
- GRWG $1.77
- SPRO $1.87
- Analyst Decision
- GRWG Strong Buy
- SPRO Buy
- Analyst Count
- GRWG 1
- SPRO 4
- Target Price
- GRWG $2.50
- SPRO $5.00
- AVG Volume (30 Days)
- GRWG 882.7K
- SPRO 798.2K
- Earning Date
- GRWG 08-11-2025
- SPRO 08-12-2025
- Dividend Yield
- GRWG N/A
- SPRO N/A
- EPS Growth
- GRWG N/A
- SPRO N/A
- EPS
- GRWG N/A
- SPRO N/A
- Revenue
- GRWG $164,108,000.00
- SPRO $48,576,000.00
- Revenue This Year
- GRWG N/A
- SPRO N/A
- Revenue Next Year
- GRWG N/A
- SPRO N/A
- P/E Ratio
- GRWG N/A
- SPRO N/A
- Revenue Growth
- GRWG N/A
- SPRO N/A
- 52 Week Low
- GRWG $0.82
- SPRO $0.51
- 52 Week High
- GRWG $2.33
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- GRWG 77.17
- SPRO 35.23
- Support Level
- GRWG $1.45
- SPRO $1.80
- Resistance Level
- GRWG $1.64
- SPRO $2.38
- Average True Range (ATR)
- GRWG 0.13
- SPRO 0.12
- MACD
- GRWG 0.05
- SPRO -0.02
- Stochastic Oscillator
- GRWG 97.47
- SPRO 12.07
About GRWG GrowGeneration Corp.
GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.